166 related articles for article (PubMed ID: 35551087)
1. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy.
Davidson TM; Foster N; Lucien F; Markovic S; Dong H; Winters JL; Park SS; Orme JJ
BMJ Open; 2022 May; 12(5):e050112. PubMed ID: 35551087
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles.
Orme JJ; Enninga EAL; Lucien-Matteoni F; Dale H; Burgstaler E; Harrington SM; Ball MK; Mansfield AS; Park SS; Block MS; Markovic SN; Yan Y; Dong H; Dronca RS; Winters JL
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817395
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
5. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
6. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Bando Y; Hinata N; Omori T; Fujisawa M
BMJ Open; 2019 Dec; 9(12):e030522. PubMed ID: 31826889
[TBL] [Abstract][Full Text] [Related]
9. Soluble PD-L1 as an early marker of progressive disease on nivolumab.
Mahoney KM; Ross-Macdonald P; Yuan L; Song L; Veras E; Wind-Rotolo M; McDermott DF; Stephen Hodi F; Choueiri TK; Freeman GJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131863
[TBL] [Abstract][Full Text] [Related]
10. Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
Crabb S; Wickens R; Jane-Bibby S; Dunkley D; Lawrence M; Knight A; Jones R; Birtle A; Huddart R; Linch M; Martin J; Coleman A; Boukas K; Markham H; Griffiths G
BMC Cancer; 2023 Sep; 23(1):885. PubMed ID: 37726695
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
13. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol.
Faqihi F; Alharthy A; Alodat M; Asad D; Aletreby W; Kutsogiannis DJ; Brindley PG; Karakitsos D
Trials; 2020 Jun; 21(1):506. PubMed ID: 32513290
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
[TBL] [Abstract][Full Text] [Related]
17. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma.
Serratì S; Di Fonte R; Porcelli L; De Summa S; De Risi I; Fucci L; Ruggieri E; Marvulli TM; Strippoli S; Fasano R; Rafaschieri T; Guida G; Guida M; Azzariti A
J Exp Clin Cancer Res; 2023 Sep; 42(1):251. PubMed ID: 37759291
[TBL] [Abstract][Full Text] [Related]
18. Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.
Niu M; Liu Y; Yi M; Jiao D; Wu K
Front Immunol; 2022; 13():827921. PubMed ID: 35386715
[TBL] [Abstract][Full Text] [Related]
19. Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Khan M; Zhao Z; Arooj S; Fu Y; Liao G
Front Immunol; 2020; 11():587460. PubMed ID: 33329567
[TBL] [Abstract][Full Text] [Related]
20. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
